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ABSTRACT
Objectives: To assess the utility of the display
standardisation of diffusion-weighted MRI (DWI) and to
compare the effectiveness of DWI and ﬂuid-attenuated
inversion recovery (FLAIR) MRI for the diagnosis of
sporadic CreutzfeldteJakob disease (sCJD).
Design: A reliability and agreement study.
Setting: Thirteen MRI observers comprising eight
neurologists and ﬁve radiologists at two universities in
Japan.
Participants: Data of 1.5-Tesla DWI and FLAIR were
obtained from 29 patients with sCJD and 13 controls.
Outcome measures: Standardisation of DWI display
was performed utilising b0 imaging. The observers
participated in standardised DWI, variable DWI (the
display adjustment was observer dependent) and
FLAIR sessions. The observers independently
assessed each MRI for CJD-related lesions, that is,
hyperintensity in the cerebral cortex or striatum, using
a continuous rating scale. Performance was evaluated
by the area under the receiver operating characteristics
curve (AUC).
Results: The mean AUC values were 0.84 (95% CI
0.81 to 0.87) for standardised DWI, 0.85 (95% CI 0.82
to 0.88) for variable DWI and 0.68 (95% CI 0.63 to
0.72) for FLAIR, demonstrating the superiority of DWI
(p<0.05). There was a trend for higher intraclass
correlations of standardised DWI (0.74, 95% CI 0.66 to
0.83) and variable DWI (0.72, 95% CI 0.62 to 0.81)
than that of FLAIR (0.63, 95% CI 0.53 to 0.74),
although the differences were not statistically
signiﬁcant.
Conclusions: Standardised DWI is as reliable as
variable DWI, and the two DWI displays are superior to
FLAIR for the diagnosis of sCJD. The authors propose
that hyperintensity in the cerebral cortex or striatum on
1.5-Tesla DWI but not FLAIR can be a reliable
diagnostic marker for sCJD.
INTRODUCTION
Reliable detection of CreutzfeldteJakob
disease (CJD) is imperative for infection
control and treatment. MRI is useful for the
early diagnosis of CJD,
1 2 whereas the utility
of EEG and conventional cerebrospinal ﬂuid
(CSF) tests have been limited.
3 Diffusion-
weighted imaging (DWI) and ﬂuid-attenu-
ated inversion recovery (FLAIR) are key
techniques for the diagnosis of sporadic CJD
(sCJD) with high sensitivity and speciﬁcity
when assessed by expert neurologists or
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ARTICLE SUMMARY
Article focus
- Evaluation of the reliability of diffusion-weighted
imaging (DWI) display standardisation for the
diagnosis of sporadic CreutzfeldteJakob disease
(sCJD).
- Comparison between DWI and ﬂuid-attenuated
inversion recovery (FLAIR) for the diagnosis of
sCJD.
Key messages
- Standardised DWI display is as reliable as
observer-dependent DWI display.
- DWI is superior to FLAIR for the diagnosis of
sCJD.
- Hyperintensity in the cerebral cortex or striatum
on 1.5-Tesla DWI but not FLAIR can be a reliable
diagnostic marker for sCJD.
Strengths and limitations of this study
- Strength of this study is the large number of
physicians who participated in the observer
performance study.
- This study was limited by the retrospective
nature that may lead to a selection bias.
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145However, the utility of MRI for
general neurologists or radiologists who are not familiar
with diagnosing CJD remains elusive. Moreover, stand-
ardisation of MRI methodologies, which would be
essential for the reproducible assessment of MRI ﬁnd-
ings of CJD cases, has not been achieved in previous
studies.
145DWI display conditions may particularly vary
among institutions or operators,
6 which can give rise to
inaccurate assessment of CJD-related lesions, speciﬁcally
subtle abnormalities in the cerebral cortex. Meanwhile,
although DWI seems superior to FLAIR for the detection
of CJD lesions,
5 direct comparison of the two sequences
is yet to be performed.
To address these issues, we investigated the utility of
a newly proposed standardisation method of DWI
display
6 7 and compared the effectiveness of DWI and
FLAIR for the diagnosis of sCJD, particularly for differ-
entiating between abnormal and normal signals by
neurologists and radiologists who are not necessarily
CJD experts. We conducted a multicentre, multiobserver
caseecontrol study and evaluated observer performance
with receiver operating characteristics (ROC) analysis.
METHODS
Subjects
Patients diagnosed as having sCJD by the CJD Surveil-
lance Committee of Japan
8 from October 2005 to
September 2010 were eligible to participate in this study.
The accuracy of the diagnosis was deﬁned as follows:
deﬁnite, that is, pathologically veriﬁed cases; probable,
that is, cases with neuropsychiatric manifestations
compatible with sCJD and periodic sharp wave
complexes on EEG without pathological examinations
and possible, that is, cases with the same ﬁndings as
probable sCJD but no periodic sharp wave complexes on
EEG.
89WHO criteria
10 were not applied because the
assay of CSF 14-3-3 protein, which is required by WHO
criteria, was standardised only since April 2009 in
Japan.
11 The prion protein gene (PRNP) was analysed in
the open reading frame after extracting DNA from
patients’ blood.
12 13 For neuropathological examina-
tions, brain sections were stained with routine tech-
niques, and immunohistochemistry was performed using
the mouse monoclonal antibody 3F4 (Senetek, MD
Heights, Missouri, USA).
12 For PrP
Sc typing, frozen brain
tissues were homogenised and analysed by western blot
for proteinase K-resistant PrP using the 3F4 antibody.
14
Assays for CSF g-isoform of 14-3-3 protein,
11 total s
protein (cut-off value, 1300 pg/ml)
15 and real-time
quaking-induced conversion (RT-QUIC)
16 were
performed in patients whose CSF samples were available.
The following patients were eligible as disease controls:
patients who were suspected to have prion disease by
primary physicians but were denied to have prion disease
by the Committee or those who were diagnosed as
having other neurological disorders at Tokushima
University Hospital and whose brain MRI showed no
abnormal intensity in the cerebral cortex or striatum. We
requested physicians who had referred patients to the
Committee to provide initial MRI data of eligible
patients.
This study was approved by the Medical Ethics
Committee of Kanazawa University and the Ethics
Committees of the Tokushima University Hospital and
Tokyo Medical and Dental University. Written informed
consent was obtained from all patients or their families.
Magnetic resonance imaging
DWI, b0 and FLAIR images were converted to the Digital
Imaging and Communication in Medicine format. When
the Digital Imaging and Communication in Medicine
data contained patient information, it was excluded by
one of the investigators (MH) before the observer
performance study. All MRI studies were performed on
1.5-Tesla scanners at each hospital. Quadrature detec-
tion head coils or multichannel head coils were used.
DWI was performed using the single-shot spin-echo echo
planar imaging technique with the following parameters:
repetition time, 4000e8000 ms; echo time, 70e100 ms;
b value, 1000 s/mm
2; slice thickness, 5 mm; matrix size,
128380 to 1283128; ﬁeld of view, 220e230 mm and
16e20 contiguous axial sections parallel to a line
through the anterior and posterior commissures were
obtained from each patient. The scanning parameters of
FLAIR were as follows: repetition time, 8000e10000 ms;
inversion time, 2000e2500 ms; effective echo time,
105e120 ms; matrix size, 2563192 to 3203224; ﬁeld of
view, 210e220 mm; slice thickness, 5e6 mm with
1e1.5 mm interslice gaps and 19 20 slices per patient.
Display methods
Two display methods were used for DWI: standardised
and variable. In the standardised display, the window
width and level settings were constant for all evaluations
and could not be changed. Details of the standardised
display have been reported elsewhere.
6 In brief, the
window width and level were as follows: window width ¼
SIb0 and window level ¼ SIb0/2, where SIb0 represents the
signal intensity in the normal-appearing subcortical
region on b0 imaging.
6 One radiologist (MH) manually
measured SIb0 within a circular region of interest. The
calculated window width and level were applied to all
images. In the variable display mode, regarded as the
most reliable for assessment of DWI, each observer was
able to change the window width and level settings on the
monitor according to preference. FLAIR was assessed
with the variable display method because no standardised
methods are currently available for FLAIR display.
Observer performance study
Eight neurologists (6e27 years of experience; mean,
12 years; board certiﬁed, six) and ﬁve radiologists
(5e25 years of experience; mean, 12.8 years; board
certiﬁed, four; neuroradiologist, one) participated in the
observer performance study at The University of
Tokushima Graduate School (persons, six; neurologists,
three) and Tokyo Medical and Dental University
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Before the test, the observers were informed that the
purpose of the study was to evaluate their performance
in detecting MRI lesions compatible with CJD, that is,
hyperintensity in the cerebral cortex or striatum,
regardless of signal changes in other regions including
the thalamus. Three sessions were conducted: stand-
ardised DWI, variable DWI and FLAIR. To reduce the
effect of learning, the interval between reading sessions
was 1 week or longer. The order of the three sessions was
randomised among the observers. Using computer
randomisation, images of patients with and without sCJD
were intermixed. All cases were presented in the same
randomised order to the observers in each session. Each
observer independently viewed all slices of each MRI
study on the same type of monitors (Let’snote, Pana-
sonic, Osaka, Japan) using INTAGE Realia Professional
(Cubernet, Tokyo, Japan) run on Windows XP (Micro-
soft). The observers were allowed to adjust the window
width and level only in variable DWI and FLAIR sessions
but not in the standardised DWI session. Observers were
blinded to any clinical information including age, sex
and diagnosis.
Each observer used a continuous rating scale of a line-
marking method to rate his or her conﬁdence level on
the paper format independently. At the left end of the
line, a conﬁdence level that lesions compatible with CJD
were deﬁnitely absent was indicated, whereas at the right
end, a conﬁdence level that lesions were deﬁnitely
present was indicated. Intermediate levels of conﬁdence
were indicated by the different positions on the line
between the two ends. The distance between the left end
and the marked point was converted to a conﬁdence
level that could range from 0 to 100, as described
elsewhere.
17
Statistical analyses
Observer performance was evaluated using ROC analysis
with SPSS V.19 (IBM). The ROC curves for each observer
indicated the ratio of the true-positive fraction to the
false-positive fraction at each conﬁdence level. The area
under the ROC curve (AUC) was used to compare
observer performance for accurately detecting CJD
lesions. Intraclass correlations were calculated in the
neurologist group, the radiologist group and for all
observers by two-way random consistency measures using
the SPSS software. In all the analyses, p values of <0.05
were considered statistically signiﬁcant.
RESULTS
Patients and controls
MRI data from 85 patients were provided. Of these, 42
subjects from 15 hospitals (including authors’ institu-
tions) were eligible for this study after excluding cases
that were diagnosed as having non-sporadic CJD or
lacked the required MRI sequences. This study cohort
included 29 patients with sCJD (men, 11; mean age,
71 years; duration before MRI, 4.466.1 months), three
patients who were suspected of CJD but eventually
diagnosed as negative by the Committee and 10 patients
diagnosed as having other neurological disorders. Of the
29 sCJD patients, four had deﬁnite, 24 had probable and
one had possible CJD. Twenty-six cases underwent PRNP
analysis, 24 were homozygous for methionine at codon
129 and two were heterozygous with methionine and
valine at codon 129. Of the four deﬁnite cases, PrP
Sc was
type 1 in two cases, type 1+2 in one case and type 2 in
one case. Eleven of 15 CSF samples from probable sCJD
cases were positive for PrP
Sc by RT-QUIC (table 1).
Diagnoses for three prion-denied patients were
immune-mediated encephalopathy, juvenile Alzheimer’s
disease and frontotemporal dementia. Other neurolog-
ical controls were diagnosed with Alzheimer’s disease,
Parkinson’s disease, spinocerebellar degeneration,
vascular dementia, old cerebral infarction, benign
paroxysmal positional vertigo, dizziness, temporal arter-
itis, cervical spondylosis and diabetic neuropathy.
Diagnostic performance
We investigated the diagnostic performance of stand-
ardised DWI, variable DWI and FLAIR images assessed
by eight neurologists and ﬁve radiologists using ROC
analysis. Mean AUC values obtained from the three
sessions were compared within the neurologist group,
the radiologist group and all observers (ﬁgure 1,
table 2). The AUC values for standardised and variable
DWI were not different within each professional group
or for the total observer group. On the other hand, AUC
values for FLAIR were signiﬁcantly lower than DWI
displayed by either method (p<0.05). Representative
MRI scans are shown in ﬁgure 2.
Rating agreement
To measure the extent to which the observers agreed
when rating the MRI ﬁndings, intraclass correlations
were calculated. The intraclass correlations of the
standardised DWI (0.74, 95% CI 0.66 to 0.83) and vari-
able DWI (0.72. 95% CI 0.62 to 0.81) tend to be higher
than that of FLAIR (0.63, 95% CI 0.53 to 0.74), speciﬁ-
cally in the neurologist group, although the differences
were not signiﬁcant (ﬁgure 3).
DISCUSSION
We demonstrated that standardised DWI was as useful as
variable DWI and that both DWI displays are superior to
FLAIR for the diagnosis of sCJD when assessed by
multiobservers with various specialty backgrounds.
Our standardisation method of DWI display was orig-
inally proposed as an easy-to-use way to decide the
window width and level for DWI even in emergency
settings.
6 Indeed, this method was demonstrated as
useful for detecting acute ischaemic lesions on DWI.
7
Results of the present study show that the stand-
ardisation method is also reliable for diagnosis of sCJD,
in which DWI is one of the key sequences. We suggest
some advantages of standardised DWI over variable DWI,
although there was no statistical difference between the
two methods. First, standardised DWI can be helpful for
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softcopies. Second, even for doctors who can readily
refer to softcopies and thus variable DWI, the stand-
ardisation method can simplify assessment procedure
without any disadvantages. Third, the standardisation
can facilitate direct comparison of DWI ﬁndings from
different CJD patients.
DWI and FLAIR have been reported as useful markers
for the diagnosis of CJD. Of these, DWI has been
assumed to be the most sensitive, although without
direct evidence.
1 51 8Hyperintensity in the cerebral
cortices, the striatum or both indicates the diagnosis of
CJD. The striatum hyperintensity is anterior dominant at
early stages of the disease.
19 MRI lesion proﬁles report-
edly differ among molecular subtypes of sCJD,
20 21 which
was not reproduced in a recent study.
5 Zerr et al
4
proposed that high-signal abnormalities in caudate
nucleus and putamen or at least two cortical regions
(temporal, parietal or occipital lobes) either in DWI or
FLAIR together with typical clinical signs can be diag-
nostic for probable sCJD. Based partly upon their report,
‘high signal in caudate/putamen on MRI brain scan’ has
Figure 1 Receiver operating
characteristic curves for each
display in diagnosis of sporadic
CreutzfeldteJakob disease. (A)
Neurologists, (B) radiologists and
(C) all observers. The true rate
(sensitivity) is plotted as a function
of the false-positive rate
(1   speciﬁcity). DWI, diffusion-
weighted imaging; FLAIR, ﬂuid-
attenuated inversion recovery; sDWI, standardised DWI; vDWI, variable DWI.
Table 1 Clinical proﬁles of patients with sporadic CreutzfeldteJakob disease
No Age/sex Diagnosis Codon129/PrP
Sc 14-3-3/total s RT-QUIC
Pre-MRI
duration (months)
1 69/M Deﬁnite MM/1 +/+ +  2*
2 77/F Deﬁnite MM/1 +/+ + 19
3 75/F Deﬁnite ND/1+2 +/+ + 3
4 65/M Deﬁnite MM/2  /   12
5 69/M Probable MM ND   0.5
6 72/F Probable MM ND ND 0.5
7 77/F Probable MM  /  + 0.5
8 72/M Probable MM ND ND 1
9 63/M Probable MM +/+ + 1.5
10 88/F Probable MM ND ND 1.5
11 75/M Probable MV ND ND 1.5
12 56/M Probable MM +/+ + 2
13 67/M Probable MM +/+   2
14 70/M Probable MM +/+ + 2
15 70/F Probable MM +/+ + 2
16 74/F Probable MM +/+   2
17 84/F Probable MM +/  +2
18 85/F Probable MM  /+ + 2
19 49/F Probable ND +/+ + 2
20 74/F Probable MV +/+ + 2.5
21 54/F Probable ND ND ND 2.5
22 61/M Probable MM ND ND 3
23 72/F Probable MM +/   3
24 81/F Probable MM  /  +3
25 70/M Probable MM +/+ + 6
26 83/F Probable MM +/+ ND 9
27 67/F Probable MM +/+   15
28 84/F Probable MM +/+   26
29 57/F Possible MM ND ND 4
*MRI was obtained 2 months before the symptom onset.
2
MM, homozygous for methionine; MV, heterozygous with methionine and valine; ND, not done; RT-QUIC, real-time quaking-induced
conversion.
4 Fujita K, Harada M, Sasaki M, et al. BMJ Open 2012;2:e000649. doi:10.1136/bmjopen-2011-000649
Reliability of DWI and FLAIR for diagnosis of sporadic CJDbeen used as one of the laboratory ﬁndings in the
diagnostic criteria for probable sCJD in the European
CJD Surveillance System (EUROCJD) since January
2010.
22 However, their criteria did not distinguish DWI
and FLAIR, thereby maintaining ambiguity about the
diagnostic values of MRI in situations where DWI is not
available. Our data indicate that FLAIR without DWI is
unreliable for the diagnosis of sCJD. On the other hand,
high signals in the cerebral cortex have not been
regarded as diagnostic in the EUROCJD criteria, prob-
ably because cortical abnormalities are less reliable on
conventional MRI. Our results suggest that, using
standardised or variable DWI but not FLAIR, cortical
signals can also be used as a diagnostic marker.
Meanwhile, Young et al
23 reported that the sensitivity
and the speciﬁcity of DWI and FLAIR for the diagnosis
of CJD are 91% and 95%, respectively. More recently,
Vitali et al
5 reported that hyperintensity greater on DWI
than FLAIR is diagnostic for sCJD, whereas hyper-
intensity greater on FLAIR than DWI is characteristic for
non-prion rapidly progressive dementia. Furthermore,
reduction of apparent diffusion coefﬁcient in subcortical
(striatum) hyperintensity regions on DWI is supportive
for sCJD.
52 42 5These ﬁndings can be greatly helpful for
differentiating sCJD from other rapidly progressive
dementia. However, assessment of FLAIR lesions tends
to vary among physicians, particularly among neurolo-
gists, as shown by the present study, and standardised
methods for FLAIR or apparent diffusion coefﬁcient
map have not been established until date. Therefore,
clinical criteria which require DWI but not necessarily
FLAIR or apparent diffusion coefﬁcient will be more
readily applicable.
As many as 13 neurologists and radiologists from
different institutions participated in the observer
performance study, although the sample size of patients
was relatively small. Notably, the observers had various
specialty backgrounds such as stroke neurologists,
neurophysiologists, experts in dementia or prion disease
and general and neuroradiologists. This variety simulates
practical situations in which the diagnosis of suspected
CJD cases may be made by physicians who do not
necessarily specialise in prion disease.
This study has some limitations. First, we did not
evaluate patterns of cortical involvement suggestive of
sCJD
4 5 because we had to address whether DWI or
FLAIR is suitable for detecting cortical lesions in the ﬁrst
place. Second, we did not assess the difference among
sCJD subtypes
21 because majority of our cases had
a typical phenotype and were homozygous for methio-
nine; thus, they were compatible with MM1 sCJD. Until
date, MM2 thalamic-type sCJD remains a diagnostic
challenge in MRI-based assessment; thalamic hypo-
perfusion or hypometabolism on SPECT or PET can be
useful.
26 Third, majority of the control patients were not
those who were suspected to have CJD. However, the
Figure 2 Representative MRI of
a sporadic CreutzfeldteJakob
disease patient (case 17).
Abnormal hyperintensity in the
cerebral cortex is evident on
standardised diffusion-weighted
imaging (A, arrow) but obscure on
ﬂuid-attenuated inversion recovery
(B, arrow).
Table 2 Areas under the receiver operating characteristic curves
Neurologists Radiologists All observers
sDWI 0.86 (0.82 to 0.90) 0.82 (0.77 to 0.88) 0.84 (0.81 to 0.87)
vDWI 0.86 (0.82 to 0.90) 0.83 (0.77 to 0.89) 0.85 (0.82 to 0.88)
FLAIR 0.69 (0.63 to 0.75) 0.66 (0.58 to 0.73) 0.68 (0.63 to 0.72)
Means (95% CIs) are indicated.
DWI, diffusion-weighted imaging; FLAIR, ﬂuid-attenuated inversion recovery; sDWI, standardised DWI; vDWI, variable DWI.
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Reliability of DWI and FLAIR for diagnosis of sporadic CJDprinciple aim of the present study was to establish
a display method, which reliably distinguishes potentially
CJD-associated signals from normal signals. Thus, our
results provide a practical foundation for utilising DWI
as a general diagnostic marker of sCJD when combined
with previous ﬁndings.
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Although neuropathological conﬁrmation of the
diagnosis of sCJD was obtained in few cases, we
performed RT-QUIC, a newly established CSF PrP
Sc
ampliﬁcation assay which achieved >80% sensitivity and
100% speciﬁcity for CJD.
16 Overall, 15 of 29 cases
(51.7%) were pathologically proven or conﬁrmed by RT-
QUIC to have CJD. There were no signiﬁcant differences
in MRI ﬁndings between sCJD patients with and without
positive results of CSF 14-3-3 protein, total s protein or
RT-QUIC. It will be important to further evaluate accu-
rate diagnostic ability (sensitivity and speciﬁcity) of
DWI in a prospective cohort of suspected CJD patients,
that is, consecutive patients registered to the CJD
surveillance who will also undergo CSF conﬁrmation
tests or neuropathological analyses.
In conclusion, we suggest that hyperintensity in the
cerebral cortex or striatum assessed on the standardised
or variable DWI scanned with 1.5-Tesla machines can be
a reliable ﬁrst-line on-site diagnostic marker for sCJD.
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